Transaction DateRecipientSharesTypePriceValue
21st October 2020Bernard J Kelley2,500Open or private sale$14.00$35,006.75
13th October 2020Alison Moore11,031Exercise of derivative$2.27$25,040.37
13th October 2020Alison Moore11,031Open or private sale$42.00$463,302.00
12th October 2020Alison Moore24,233Open or private sale$42.00$1,017,786.00
12th October 2020Alison Moore24,233Exercise of derivative$2.27$55,008.91
9th October 2020Byron L Dorgan25,000Exercise of derivative$10.63$265,750.00
9th October 2020Alison Moore30,199Exercise of derivative$2.27$68,551.73
9th October 2020Alison Moore39,509Open or private sale$41.00$1,619,869.00
9th October 2020Byron L Dorgan25,000Open or private sale$13.54$338,527.50
8th October 2020Byron L Dorgan25,000Exercise of derivative$10.63$265,750.00
Codexis logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 5/10.

Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels.

Ticker: CDXS
Sector: Process Industries
Industry: Chemicals: Specialty
SEC Central Index Key (CIK): 1200375
Employees: 161
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $76 M (0%)
Inventory, Net: $686 Th (0%)
Assets, Current: $106 M (-6%)
Property, Plant and Equipment, Net: $7 M (8%)
Other Assets, Noncurrent: $391 Th (119%)
Assets: $142 M (-4%)
Accounts Payable, Current: $3 M (0%)
Accrued Liabilities, Current: $7 M (0%)
Liabilities, Current: $19 M (23%)
Other Liabilities, Noncurrent: $1 M (1%)
Liabilities: $47 M (7%)
Common Stock, Value, Issued: $6 Th (0%)
Common Stock, Shares, Issued: $59 Th (0%)
Retained Earnings (Accumulated Deficit): $356 M (4%)
Stockholders' Equity (Parent): $95 M (0%)
Liabilities and Equity: $142 M (-4%)
Revenue: $15 M (0%)
Cost of Revenue: $2 M (-59%)
Research and Development: $11 M (-50%)
Operating Income/Loss: $6 M (-56%)
Income before taxes: $6 M (-55%)
Provision for income taxes: $307 Th (-1%)